Patents Examined by Glennon H. Hollrah
  • Patent number: 5532415
    Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: July 2, 1996
    Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.
    Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin, Alex Veinberg
  • Patent number: 5514680
    Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal.Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.
    Type: Grant
    Filed: November 5, 1993
    Date of Patent: May 7, 1996
    Assignees: The State of Oregon, acting by and through The Oregon State Board of Higher Education, acting for and on behalf of The Oregon Health Sciences University, The University of Oregon, The Regents of the University of California
    Inventors: Eckard Weber, John F. W. Keana
  • Patent number: 5514710
    Abstract: The invention describes the synthesis and use of photoactivated (or caged) fluorescent dyes. Upon illumination at less than about 400 nm the caged dyes release highly fluorescent, water soluble hydroxypyrenesulfonic acid dyes according to the following equation: ##STR1## X, Y, and Z are independently sulfonic acid, a sulfonic acid salt, a hydroxyl group, or hydrogen, with at least one of X, Y, and Z being a sulfonic acid or sulfonic acid salt. LINK is either an ether linkage or a carbonate linkage. BLOCK is a caging group whose photolysis results in liberation of a free hydroxypyrenesulfonic acid dye.The caged fluorescent dyes are useful for application in aqueous solutions, including fluids of biological origin. The caged dyes of the present invention are especially useful for flow tagging velocimetry.
    Type: Grant
    Filed: January 11, 1994
    Date of Patent: May 7, 1996
    Assignee: Molecular Probes, Inc.
    Inventors: Richard P. Haugland, Kyle R. Gee
  • Patent number: 5503853
    Abstract: Prophylactic and therapeutic applications of peroxidases for the manufacture of medicaments for the treatment and prevention and treatment of enveloped virus infections and, in particular, of herpes simplex and immunodeficiency virus infections. The medicaments include a peroxidase, a substrate and a peroxide in a pharmaceutically acceptable carrier. Peroxidases of the medicaments include lactoperoxidase and myeloperoxidase. The medicaments are formulated with a pharmaceutically acceptable carrier for topical, oral and injectable administration to individuals in need thereof.
    Type: Grant
    Filed: February 19, 1993
    Date of Patent: April 2, 1996
    Inventors: Alex Bollen, Nicle Moguilevsky, Michel Pourtois
  • Patent number: 5494934
    Abstract: A compound of formula (I): ##STR1## in which: R.sub.1 represents substituted or unsubstituted phenyl or (C.sub.3 -C.sub.7) cycloalkyl,R.sub.2 represents trifluoromethyl or (C.sub.3 -C.sub.4) cycloalkyl,A represents --CH.sub.2 --, --CH.dbd.N--, .dbd.N-- or --NH--,R.sub.3 and R.sub.4, which may be identical or different, represent hydrogen or linear or branched (C.sub.1 -C.sub.6) alkyl or, with the nitrogen atoms to which they are attached, form a 5- or 6-membered heterocycle,R represents either hydrogen in the case where A=--CH.sub.2 --, --CH.dbd.N-- or --NH--, or a bond of the group A when the latter is equal to .dbd.N--,its enantiomers and epimers as well as its addition salts with a pharmaceutically acceptable acid.Medicine products.
    Type: Grant
    Filed: November 4, 1991
    Date of Patent: February 27, 1996
    Assignee: Adir et Compagnie
    Inventors: Charles Malen, Jean-Michel Lacoste, Guillaume de Nanteuil
  • Patent number: 5491157
    Abstract: Methods and compositions utilizing 2-amino-5-thiazolyl thiocyanate compounds and their derivatives for the control of soilborne fungi and disease caused thereby are described.
    Type: Grant
    Filed: May 10, 1993
    Date of Patent: February 13, 1996
    Assignee: Eastman Kodak Company
    Inventors: V. James Spadafora, Thomas E. Brady, Masatoshi Motoyoshi
  • Patent number: 5491264
    Abstract: Isophorone diamine is prepared from isophorone nitrile by imination using a supported heteropoly acid catalyst to form the ketimine followed by the reduction of the ketimine to form the diamine.
    Type: Grant
    Filed: September 12, 1994
    Date of Patent: February 13, 1996
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Frank E. Herkes, Kostantinos Kourtakis
  • Patent number: 5491263
    Abstract: A process is disclosed for producing a substituted ethylenediamine, the process comprising reacting an oxazolidinone with a secondary amine or an alkanolamine. The process includes, in one aspect, reacting precursors of the oxazolidinone in situ.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: February 13, 1996
    Assignee: The Dow Chemical Company
    Inventors: Peter C. Rooney, Michael O. Nutt
  • Patent number: 5491243
    Abstract: This invention provides a stereospecific process for the synthesis of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a key intermediate in the synthesis of duloxetine.
    Type: Grant
    Filed: July 18, 1994
    Date of Patent: February 13, 1996
    Assignee: Eli Lilly and Company
    Inventor: Richard A. Berglund
  • Patent number: 5489695
    Abstract: N-Phenylsulfonyl-N'-pyrimidinyl-,-N'-triazinyl- and-N'-triazolylureas and -thioureas of formula I ##STR1## in which X is oxygen, sulfur, SO or SO.sub.2 ; W is oxygen or sulfur, R.sub.1 is hydrogen or methyl; R.sub.2 is hydrogen, fluorine, chlorine, bromine, iodine, (X).sub.n R.sub.3, NO.sub.2, NR.sub.4 R.sub.5, --C.tbd.CR.sub.6, ##STR2## or cyano; n is the number 0 or 1; R.sub.3 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkyl which is substituted by 1-4 halogen atoms, C.sub.1 -C.sub.3 alkoxy or C.sub.1 -C.sub.3 alkylthio; or C.sub.2 -C.sub.4 alkenyl or C.sub.2 -C.sub.4 alkenyl which is substituted by 1-4 halogen atoms; R.sub.4 is hydrogen, CH.sub.3 O, CH.sub.3 CH.sub.2 O or C.sub.1 -C.sub.3 alkyl; R.sub.5 is hydrogen or C.sub.1 -C.sub.3 alkyl; R.sub.6 is hydrogen, methyl or ethyl; R.sub.7 is hydrogen or methyl; Z is ##STR3## E is methine or nitrogen; R.sub.8 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkoxy, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.4 haloalkylthio, C.sub.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: February 6, 1996
    Assignee: Ciba-Geigy Corporation
    Inventor: Willy Meyer
  • Patent number: 5489708
    Abstract: The reduction of the O-alkyl isomer content of 5-[N-(2-acetoxyethyl)acetoxyacetamido]-N,N'-bis(2,3-diacetoxypropyl)-2,4,6 -triiodoisophthalamide to thereby reduce and/or eliminate the production of impurities comparatively more difficult to remove during the purification of crude ioversol.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: February 6, 1996
    Assignee: Mallinckrodt Medical, Inc.
    Inventors: Allan R. Bailey, Sharad S. Sathe, Andre T. Spears, Richard C. Wisneski, Mills T. Kneller
  • Patent number: 5488167
    Abstract: Provided by the present invention is a process for the biocatalytic synthesis of optically pure sphingosines from achiral starting material. The stereoisomers of sphingosine are prepared from chiral arene diols using stereospecific reaction techniques to obtain the desired sphingosine or derivative thereof.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: January 30, 1996
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventor: Tomas Hudlicky
  • Patent number: 5488165
    Abstract: A modified natural clinoptilolite, produced by treating a natural clinoptilolite with a suitable mineral acid or with a suitable alkali and then with a suitable mineral acid, is used as a catalyst in a process for the conversion of methanol and ammonia to give a product containing at least 50% by weight of monomethylamine.
    Type: Grant
    Filed: December 30, 1991
    Date of Patent: January 30, 1996
    Assignee: Zeofuels Research (Proprietary) Limited
    Inventors: Graham J. Hutchin, Themistoclis Themistocleous, Richard G. Copperthwaite
  • Patent number: 5488049
    Abstract: The present invention is directed to the use of benzothiadiazide derivatives as nootropic agents to treat memory and learning disorders.
    Type: Grant
    Filed: December 10, 1993
    Date of Patent: January 30, 1996
    Assignee: FIDIA - Georgetown Institute for the Neuro-Sciences
    Inventors: Erminio Costa, Alessandro Guidotti, Mario Baraldi, Mariella Bertolino, Maria DiBella, Stefano Vicini
  • Patent number: 5488166
    Abstract: Provided by the present invention is a process for the biocatalytic synthesis of optically pure sphingosines from achiral starting material. The stereoisomers of sphingosine are prepared from chiral arene diols using stereospecific reaction techniques to obtain the desired sphingosine or derivative thereof.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: January 30, 1996
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventor: Tomas Hudlicky
  • Patent number: 5486510
    Abstract: A mixture of .beta.-sitosterol glucoside and .beta.-sitosterol is administered to persons for the modulation or control of immune responses. The two compounds may be added in admixture or sequentially. Diseases such as viral and bacterial infections, autoimmune diseases, psoriasis, ezcema, asthma, cancer may be treated.
    Type: Grant
    Filed: November 8, 1993
    Date of Patent: January 23, 1996
    Assignee: Rooperol (NA) NV
    Inventors: Patrick J. D. Bouic, Carl F. De Vosa Albrecht
  • Patent number: 5482974
    Abstract: A compound for controlling Take-all disease of plants by applying, preferably to the seed prior to planting, a fungicide of the formula ##STR1## wherein R.sup.2 is ethyl, iso-propyl, propyl or allyl; A is N(CH.sub.3).sub.1-n H.sub.n R.sup.5 or OR.sup.6 wherein n is 0 or 1, R.sup.5 is (CH.sub.3).sub.m (CH.sub.3 CH.sub.2).sub.3-m C, 1-methylcyclopentyl, 1-methylcyclohexyl or 2,3-dimethyl-2-butyl wherein m is 0, 1, 2 or 3 and R.sup.6 is independently R.sup.5 or 2,3,3-trimethyl-2-butyl;R.sup.3 is H or independently R.sup.4 ; andR.sup.4 is halo or CH.sub.3 ;with the proviso that when A is N(CH.sub.3).sub.1-n H.sub.n R.sup.5, if R.sup.3 is H and R.sup.5 is 1-methyl-1-cyclohexyl or (CH.sub.3).sub.m (CH.sub.2 CH.sub.3).sub.3-m C, where m is 0 or 3, or if R.sup.3 is halo and R.sup.5 is (CH.sub.3).sub.m (CH.sub.3 CH.sub.2).sub.3-m C, where m is 3, then R.sup.2 cannot be ethyl;and with the proviso that when A is OR.sup.6 then m is equal to or less than 2, and if R.sup.3 is H or halo and R.sup.
    Type: Grant
    Filed: March 8, 1994
    Date of Patent: January 9, 1996
    Assignee: Monsanto Company
    Inventors: Dennis P. Phillion, Karey A. Van Sant, Daniel M. Walker
  • Patent number: 5480858
    Abstract: Cyclohexanedione derivatives of the formula (I), ##STR1## wherein R.sup.1 is a C.sub.1 -C.sub.6 alkyl group, R.sup.2 is a C.sub.1 -C.sub.4 alkyl group, each of R.sup.3, R.sup.4 and R.sup.5 is independently hydrogen or a C.sub.1 -C.sub.4 alkyl group, and n is an integer of 0 to 2, or salts thereof exhibit high selectivity for corn, wheat and barley, and can control gramineous weeds and broad-leaved weeds at low dosages.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: January 2, 1996
    Assignee: Idemitsu Kosan Co., Ltd.
    Inventors: Masashi Sakamoto, Mitsuru Shibata, Ichiro Nasuno, Kazuyoshi Koike
  • Patent number: 5480902
    Abstract: There are provided fungicidal thienyl- and furylpyrrole compounds of formula I ##STR1## Further provided are compositions and methods comprising those compounds for the protection of plants from fungal infestation and disease.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: January 2, 1996
    Assignee: American Cyanamid Company
    Inventors: Roger W. Addor, Joseph A. Furch, III, Laurelee A. Duncan
  • Patent number: 5480585
    Abstract: A photoresist stripping liquid composition comprising an alkanol amine compound, a sulfone compound or sulfoxide compound, and a hydroxy compound. The composition is excellent in its photoresist stripping performance, safety and working efficiency, and does not cause corrosion on a substrate possessing a metal film.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: January 2, 1996
    Assignee: Nagase Electronic Chemicals, Ltd.
    Inventors: Shinichiro Shiotsu, Yoshiaki Horiuchi